课题基金 / 基金详情

Development of Oral Small Molecule PCSK9 Antagonist

Development of Oral Small Molecule PCSK9 Antagonist
口服小分子PCSK9拮抗剂的研制
批准号:
9346559
负责人:
Nabil A Elshourbagy
金额:
$68.23万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2019-05-31
关键词:
AddressAdvanced DevelopmentAdverse effectsAnimal BehaviorAnimal ModelBindingBinding ProteinsBioavailableBiochemistryBiological AssayBiological AvailabilityBloodCardiovascular DiseasesCardiovascular systemCause of DeathCellsCholesterolCholesterol HomeostasisClinicalClinical TrialsCodeCoronary ArteriosclerosisCytochrome P450Degradation PathwayDevelopmentDietDoseDrug CompoundingDrug KineticsEducationEndoplasmic ReticulumEnsureEnzyme PrecursorsEpidemicEpidermal Growth FactorEpidermal Growth Factor ReceptorEvaluationEventExhibitsFamilial HypercholesterolemiaFatty acid glycerol estersFemaleFormulationGenesGoalsHeart DiseasesHemolysisHigh Density LipoproteinsHigh Fat DietIn VitroIndividualInterventionLDL Cholesterol LipoproteinsLabelLeadLinkLipidsLiverLow Density Lipoprotein ReceptorLow-Density LipoproteinsMethodsModelingMolecular ChaperonesMorbidity - disease rateMusNonsense MutationOralOrganOryctolagus cuniculusPatientsPeptide HydrolasesPermeabilityPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacotherapyPhasePlasmaPlasma ProteinsPopulationProtein PrecursorsRecombinantsRiskRisk FactorsRouteSafetySequence AnalysisSourceSubtilisin Like Proprotein ConvertasesSurfaceTestingToxicologyWomanWorkanalogbasecytotoxicitydrug candidatedrug marketefficacy testingextracellulargain of function mutationhigh riskhistopathological examinationhypercholesterolemiaimprovedin vivokillingslipid disorderloss of functionloss of function mutationmalemenmortalitynanocrystalnanoformulationnanomolarnovelpre-clinicalprematureprogramsscreeningsmall moleculesubcutaneoustherapeutic targettraffickinguptakevirtual

项目摘要

项目成果

Nabil A Elshourbagy的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘:
英文摘要
Project Summary/Abstract: The epidemic of cardiovascular disease (CVD) is a global phenomenon that remains the number one cause of death throughout the world, killing nearly 17.3 million people per year; a number that is expected to grow to 23.6 million by 2030. A high cholesterol level is well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the National Cholesterol Education Program (NCEP). Furthermore, patients with homozygous familial hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapy, and are at very high risk of premature cardiovascular disease. These and other patients will dramatically benefit from an aggressive treatment of hypercholesterolemia. The long-term goal of this work is to develop novel orally bioavailable drugs for cholesterol lowering. Our therapeutic target is the protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). PCSK9 controls the degradation of the LDL receptor (LDLR) in the liver and thereby contributes to cholesterol homeostasis. PCSK9 is synthesized as a precursor protein that undergoes processing. Secreted PCSK9 binds to the LDL-receptor (LDLR) and chaperones it to the degradation pathway. To achieve our goal, we identified nanomolar orally active small molecule PCSK9/LDLR antagonists and demonstrated its efficacy in animal model. As part of this Phase-II proposal, we will undertake all the work required to characterize these compounds in multiple animal models for the proof of concept and conduct safety assessment in order to advance the lead compound toward IND-enabling studies and clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oral PCSK9/LDLR antagonist direction to the clinic
  • 批准号:
    9906738
  • 项目类别:
  • 资助金额:
    $94.39万
  • 财政年份:
    2020
  • 负责人:
    Nabil A Elshourbagy
  • 依托单位:
Novel Modulators of HDL Metabolism
  • 批准号:
    8487433
  • 项目类别:
  • 资助金额:
    $75.4万
  • 财政年份:
    2009
  • 负责人:
    Nabil A Elshourbagy
  • 依托单位:
Novel Modulators of LDL Metabolism
  • 批准号:
    8646627
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2009
  • 负责人:
    Nabil A Elshourbagy
  • 依托单位:
Novel Modulators of HDL Metabolism
  • 批准号:
    7744773
  • 项目类别:
  • 资助金额:
    $27.05万
  • 财政年份:
    2009
  • 负责人:
    Nabil A Elshourbagy
  • 依托单位:
海外基金